Mayne Pharma Group Ltd (MYX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Mayne Pharma Group Ltd (MYX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3287
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:71
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Mayne Pharma Group Ltd (Mayne Pharma), formerly HalcyGen Pharmaceuticals Ltd, a subsidiary of Mayne Pharma Group Ltd, is a specialty pharmaceutical company that manufactures and markets branded and generic medicinal products. The company’s products comprise erymax capsules, kapanol capsules, doryx capsules, magnoplasm, astrix capsules and tablets, and lozanoc and itragerm capsules. It offers services such as analytical development, product development, contract manufacturing, logistics, and formulation development, others. Mayne Pharma offers its products in the dosage forms of tablets, capsules, powders, liquids, and creams. The company operates manufacturing facilities in Australia and the US. Mayne Pharma is headquartered in Adelaide, South Australia, Australia.

Mayne Pharma Group Ltd (MYX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Mayne Pharma Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Mayne Pharma Acquires Efudex from Spear Pharma 13
Mayne Pharma Acquires Rights to Foam Assets from GlaxoSmithKline for USD50 Million 14
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 15
Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 17
Mayne Pharma Acquires Brands And Related Assets For Forest Labs For US$12 Million 18
Mayne Pharma Acquires Kapanol from GlaxoSmithKline for USD15 Million 19
Venture Financing 20
HedgePath Pharma Raises USD0.6 Million in Financing 20
Partnerships 21
Mayne Pharma Enters into Distribution Agreement with IDT Australia 21
Mayne Pharma Enters Into Distribution Agreement With ISDIN For Subacap 22
Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 24
Licensing Agreements 26
HedgePath Pharma Enters into Option Agreement with University of Connecticut 26
Mayne Pharma Enters into Licensing Agreement with Nestle Skin Health 27
HedgePath Pharma Enters into Sublicensing Agreement with Mayne Pharma 28
HedgePath Pharma Amends Licensing Agreement With Mayne Pharma 29
Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 31
Equity Offering 32
HedgePath Pharma Raises USD1.6 Million in Second Tranche of Private Placement of Preferred Shares 32
HedgePath Pharma Raises USD2.4 Million in First Tranche of Private Placement of Preferred Shares 33
Mayne Pharma Raises USD257 Million in Rights Offering of Shares 34
Mayne Pharma to Raise USD212 Million in Private Placement of Shares 36
HedgePath Pharma Raises USD5.5 Million in Private Placement of Units 38
HedgePath Pharma Raises USD2.5 Million in Private Placement of Shares and Warrants 39
HedgePath Pharma Completes Private Placement of Shares for USD1.5 Million 40
Mayne Pharma Completes Private Placement Of Shares For US$16 Million 41
Mayne Pharma Group Completes Private Placement Of Shares For US$5 Million 42
Mayne Pharma Group Completes Private Placement Of Shares For US$0.14 Million 43
Mayne Pharma Group Completes Private Placement Of Shares For US$19 Million 44
Mayne Pharma Completes Final Tranche Of Private Placement Of Shares For US$4 Million 46
Acquisition 47
Mayne Pharma Acquires Libertas Pharma, Generic Pharma Company 47
Mayne Pharma Completes Acquisition Of Metrics For Up To US$120 Million 48
Mayne Pharma Group Ltd – Key Competitors 50
Mayne Pharma Group Ltd – Key Employees 51
Mayne Pharma Group Ltd – Locations And Subsidiaries 52
Head Office 52
Other Locations & Subsidiaries 52
Recent Developments 54
Strategy And Business Planning 54
Apr 18, 2018: Mayne Pharma Opens New Solid Oral-dose Manufacturing Facility In US 54
Financial Announcements 55
Feb 23, 2018: Mayne Pharma Reports 2018 Half Year Performance 55
Aug 25, 2017: Mayne Pharma Reports FY17 Results 58
Feb 24, 2017: Mayne Pharma: 2017 Half Year Release 61
Corporate Communications 64
Jun 28, 2018: Mayne Pharma Names Patrick Blake As New Director 64
May 30, 2018: Mayne Pharma Announces New Board Director 65
Mar 09, 2017: Mayne Pharma appoints new Group CFO and Company Secretary 66
Jan 16, 2017: Mayne Pharma Announces Leadership Changes 67
Other Significant Developments 69
Aug 08, 2017: Mayne Pharma Market Update 69
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71

List of Tables
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mayne Pharma Group Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Mayne Pharma Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Mayne Pharma Acquires Efudex from Spear Pharma 13
Mayne Pharma Acquires Rights to Foam Assets from GlaxoSmithKline for USD50 Million 14
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 15
Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 17
Mayne Pharma Acquires Brands And Related Assets For Forest Labs For US$12 Million 18
Mayne Pharma Acquires Kapanol from GlaxoSmithKline for USD15 Million 19
HedgePath Pharma Raises USD0.6 Million in Financing 20
Mayne Pharma Enters into Distribution Agreement with IDT Australia 21
Mayne Pharma Enters Into Distribution Agreement With ISDIN For Subacap 22
Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 24
HedgePath Pharma Enters into Option Agreement with University of Connecticut 26
Mayne Pharma Enters into Licensing Agreement with Nestle Skin Health 27
HedgePath Pharma Enters into Sublicensing Agreement with Mayne Pharma 28
HedgePath Pharma Amends Licensing Agreement With Mayne Pharma 29
Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 31
HedgePath Pharma Raises USD1.6 Million in Second Tranche of Private Placement of Preferred Shares 32
HedgePath Pharma Raises USD2.4 Million in First Tranche of Private Placement of Preferred Shares 33
Mayne Pharma Raises USD257 Million in Rights Offering of Shares 34
Mayne Pharma to Raise USD212 Million in Private Placement of Shares 36
HedgePath Pharma Raises USD5.5 Million in Private Placement of Units 38
HedgePath Pharma Raises USD2.5 Million in Private Placement of Shares and Warrants 39
HedgePath Pharma Completes Private Placement of Shares for USD1.5 Million 40
Mayne Pharma Completes Private Placement Of Shares For US$16 Million 41
Mayne Pharma Group Completes Private Placement Of Shares For US$5 Million 42
Mayne Pharma Group Completes Private Placement Of Shares For US$0.14 Million 43
Mayne Pharma Group Completes Private Placement Of Shares For US$19 Million 44
Mayne Pharma Completes Final Tranche Of Private Placement Of Shares For US$4 Million 46
Mayne Pharma Acquires Libertas Pharma, Generic Pharma Company 47
Mayne Pharma Completes Acquisition Of Metrics For Up To US$120 Million 48
Mayne Pharma Group Ltd, Key Competitors 50
Mayne Pharma Group Ltd, Key Employees 51
Mayne Pharma Group Ltd, Other Locations 52
Mayne Pharma Group Ltd, Subsidiaries 52

List of Figures
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Mayne Pharma Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Mayne Pharma Group Ltd (MYX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Empire Energy Group Ltd (EEG):企業の財務・戦略的SWOT分析
    Summary Empire Energy Group Ltd (EEGL), formerly Imperial Corp Ltd is an oil and gas company that offers exploration and production programs. The company produces and develops oil and gas assets; and has interest in onshore oil and gas fields in Mid Con property and Appalachia property. It has onsho …
  • Boehringer Ingelheim GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Boehringer Ingelheim GmbH (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG is a pharmaceutical company that conducts research, development, manufacture and sale of pharmaceuticals. It offers a wide range of products including human diseases, animal health care products and biophar …
  • US WorldMeds LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary US WorldMeds LLC (US WorldMeds) is a specialty pharmaceutical company that develops, licenses and markets healthcare products to improve lives of patients with challenging conditions and unmet medical needs. The company’s products comprise apokyn, myobloc and revonto. Its apokyn is used for …
  • Lanco Infratech Ltd (LITL):企業の財務・戦略的SWOT分析
    Lanco Infratech Ltd (LITL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • TomTom NV (TOM2):企業の戦略的SWOT分析
    TomTom NV (TOM2) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Modec Inc (6269):石油・ガス:M&Aディール及び事業提携情報
    Summary Modec Inc (Modec), a subsidiary of Mitsui Engineering & Shipbuilding Co., Ltd., is a general contractor specializing in engineering, procurement, construction and installation of floating production systems. It offers floating production storage and offloading (FPSO) vessels, floating storag …
  • Personal Genome Diagnostics Inc:製品パイプライン分析
    Summary Personal Genome Diagnostics Inc (PGD) is a genomic solution provider. The company develops next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes. It provides a portfolio of regulated tissue-based and liquid biopsy genomic products for laborat …
  • PTT Public Co Ltd Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    PTT Public Co Ltd Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary PTT Public Co Ltd (PTT) is a state-owned integrated national oil and gas, and petrochemical company. It operates in oil and natural gas, coal, power, and infrastructure businesses. The company carr …
  • Evoke Pharma Inc (EVOK):企業の財務・戦略的SWOT分析
    Summary Evoke Pharma Inc (Evoke Pharma) is a pharmaceutical company that develops drugs to treat gastrointestinal diseases (GI). The company offers Gimoti that provides predictable absorption and symptom relief during a flare regardless of gastric emptying delays and vomiting. Evoke Pharma also offe …
  • Bidstack Group Plc (BIDS):企業の財務・戦略的SWOT分析
    Bidstack Group Plc (BIDS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Choppies Enterprises Limited (CHOPPIES):企業の財務・戦略的SWOT分析
    Choppies Enterprises Limited (CHOPPIES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • MAN SE:企業の戦略・SWOT・財務分析
    MAN SE - Strategy, SWOT and Corporate Finance Report Summary MAN SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • Firestone Diamonds Plc:企業の戦略・SWOT・財務分析
    Firestone Diamonds Plc - Strategy, SWOT and Corporate Finance Report Summary Firestone Diamonds Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Capitol Health Ltd (CAJ):医療機器:M&Aディール及び事業提携情報
    Summary Capitol Health Ltd (Capitol Health) is a diagnostic imaging service provider to the healthcare market.. The company offers services such as bone densitomety, computer tomography, cone beam CT, CT angiography, doppler, echocardiography, fluoroscopy, general X-ray, magnetic resonance imaging, …
  • Flint Group SA:企業の戦略的SWOT分析
    Flint Group SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Banca Monte dei Paschi di Siena SpA:企業のM&A・事業提携・投資動向
    Banca Monte dei Paschi di Siena SpA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Banca Monte dei Paschi di Siena SpA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on …
  • Tecan Group Ltd (TECN)-医療機器分野:企業M&A・提携分析
    Summary Tecan Group Ltd (Tecan) is a provider of automated laboratory instruments and solutions for use in basic and translational research, clinical diagnostics, and drug discovery. The company develops, manufactures, and markets automated workflow solutions for laboratories and instrumentation sup …
  • PT Tigaraksa Satria Tbk (TGKA):企業の財務・戦略的SWOT分析
    PT Tigaraksa Satria Tbk (TGKA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Ko Yo Chemical (Group) Ltd (827):企業の財務・戦略的SWOT分析
    Ko Yo Chemical (Group) Ltd (827) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Seven-Eleven Japan Co., Ltd.:企業の戦略・SWOT・財務情報
    Seven-Eleven Japan Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Seven-Eleven Japan Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆